← All trials
NCT04398823
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2020
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2021
- First posted
- May 22, 2020
- Last posted
- May 22, 2020
- Enrollment
- 700
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiao Tong UniversityLead sponsor
- Zhengzhou UniversityCollaborator
- Changzhi City People's HospitalCollaborator
- Jiao Tong UniversityStudy chair
- Jiao Tong UniversityOverall official - principal investigator
- Jiao Tong UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Luoyang Central HospitalCollaborator
- BaoShan People's HospitalOverall official - principal investigator
- Ganzhou City People's HospitalCollaborator
- Shandong Maternal and Chidl Care Service CenterCollaborator
- Shandong Maternal and Chidl Care Service CenterOverall official - principal investigator
- Shanghai Construction Group HospitalOverall official - principal investigator
- Shanghai Construction Group HospitalCollaborator
- Anhui Medical UniversityCollaborator
- Sichuan UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.